Cargando…
Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer
BACKGROUND: CDK4/6 inhibitors are a promising treatment strategy in tumor therapy but are hampered by resistance mechanisms. This study was performed to reveal predictive markers, mechanisms of resistance and to develop rational combination therapies for a personalized therapy approach in bladder ca...
Autores principales: | Tong, Zhichao, Sathe, Anuja, Ebner, Benedikt, Qi, Pan, Veltkamp, Christian, Gschwend, Juergen E., Holm, Per Sonne, Nawroth, Roman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647307/ https://www.ncbi.nlm.nih.gov/pubmed/31331377 http://dx.doi.org/10.1186/s13046-019-1322-9 |
Ejemplares similares
-
Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
por: Klein, Florian G., et al.
Publicado: (2021) -
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
por: Pan, Qi, et al.
Publicado: (2017) -
STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy
por: Hindupur, Sruthi V., et al.
Publicado: (2020) -
Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy
por: Sathe, Anuja, et al.
Publicado: (2018) -
Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus
por: Koch, Jana, et al.
Publicado: (2022)